ProPhase Labs Inc (NASDAQ:PRPH) saw its stock jump 38% after securing a crucial patent for its biomarker-based system that evaluates progression risk in Barrett’s esophagus and esophageal adenocarcinoma.
The United States Patent and Trademark Office granted U.S. Patent No. 12379378-B2 for the proprietary methods supporting ProPhase’s BE-Smart™ molecular diagnostic test. This milestone follows the company’s recent announcement that the BE-Smart™ test achieved over a 95% technical success rate in identifying its panel of biomarkers.
The patented technology is compatible with both esophageal brush cytology and forceps biopsies, a combination that the company says improves early detection. Brush biopsies collect a broader range of epithelial cells, while forceps biopsies provide focused tissue samples, enhancing the risk assessment for patients with various esophageal conditions.
“This achievement, coming on the heels of our BE-Smart™ validation demonstrating greater than a 95% technical success rate and dual compatibility with both brush and forceps biopsies, solidifies our leadership in medical innovation and brings us one step closer to transforming early detection and treatment strategies for this serious condition,” said Ted Karkus, CEO of ProPhase Labs.
Filed originally in December 2023, the patent covers systems that assess risk by detecting biomarkers including ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P, and GPI. The company notes these methods may also support new treatment options, such as inhibiting cancer cell growth and increasing tumor sensitivity to cytotoxic therapies.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.